Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI
TAIPEI and SAN DIEGO,Sept. 18,2024-- Senhwa Biosciences,Inc. (TPEx: 6492),a drug development company focusing on first-in-class therapeutics for oncology,rare diseases,and infectious diseases,today a